Biosyent (RX) Q3 2025 earnings summary

Executive summary

• Achieved record Q3 2025 sales of $12.2M, up 28% year-over-year, and YTD sales of $33.4M, up 27% year-over-year.

• EBITDA for Q3 2025 was $3.63M (27% growth, 30% margin); YTD EBITDA was $9.59M (35% growth, 29% margin).

• Net income after tax for Q3 2025 was $2.7M (16% growth, 22% margin); YTD net income was $7.02M (24% growth, 21% margin).

• 61 consecutive profitable quarters, with trailing 12-month EPS of $0.75 and Q3 2025 EPS of $0.23, both trending upward.

• FeraMAX and Tibella/Tibelia products contributed significantly to profitable sales growth in Canada and internationally.

Financial highlights

• Gross profit for Q3 2025 was $9.27M, up 24% year-over-year; YTD gross profit was $25.5M, up 23%.

• Trailing twelve months cash from operations was $8.1M; working capital was $28.9M as of September 30, 2025.

• Fully diluted EPS for Q3 2025 was $0.23, up 19% year-over-year; YTD EPS was $0.61, up 28%.

Segment performance

• Canadian Pharma Q3 2025 sales were $9.9M (+19% YoY); YTD $28.4M (+16% YoY).

• International Pharma Q3 2025 sales were $1.2M (+94% YoY); YTD $3.1M (+316% YoY).

• Legacy business Q3 2025 sales were $1.2M (+83% YoY); YTD $1.9M (+73% YoY).

• FeraMAX, Tabelia/Tibella, and Inofolic brands performed strongly, with Inofolic showing promising growth from a small base.

• Combogesic business declined; company to exit this asset at the start of 2026 to reallocate investment.